AUTO 8
Alternative Names: AUTO-8Latest Information Update: 28 Jun 2025
At a glance
- Originator Autolus
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Multiple-myeloma in United Kingdom (Parenteral)
- 09 Dec 2023 Efficacy and adverse events data from phase I trial in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 22 Apr 2022 Phase-I clinical trials in Multiple myeloma in United Kingdom (Parenteral) (NCT04795882)